Citoxlab Acquires Bioanalysis Facility in Montreal

Oct 20, 2017
By Pharmaceutical Technology Editors

On Oct. 17, 2017, Citoxlab Group, a contract research organization (CRO) specializing in pre-clinical services, announced that it has acquired a new bioanalysis and biomarkers services facility in Laval, Montreal, Canada to support the company’s preclinical and clinical programs.

The 20,000 ft2-facility is a turn-key laboratory dedicated to the following: small and large molecule bioanalysis by liquid chromatography–mass spectrometry and ligand binding assays; flow cytometry; biomarkers; biodistribution by quantitative polymerase chain reaction; and immunology including anti-drug antibody, neutralizing antibody, immunophenotyping, and the Enzyme-Linked ImmunoSpot assay. According to the company, this expansion is part of a larger plan to grow their global laboratory services.

“The relocation of some of our laboratory operations to this new building will free up areas in the main building, allowing us to increase our animal room capacity, resulting in shorter lead times for our clients. The availability of this building, next door to our site in Laval, was an unexpected but excellent opportunity,” said Jean-François Le Bigot, chairman and CEO of Citoxlab Group, in a company press release.

According to Andrew Graham, site manager at Citoxlab North America, the new facility will act as a centralized location for the company’s service offerings, which include investigative studies in general and reproductive toxicology, carcinogenicity, immunology, pharmacology, pharmacokinetics, and bioanalysis/biomarkers. In November 2016, the company acquired AccelLAB, a Canadian CRO specializing in the pre-clinical assessment of new medical devices, which expanded Citoxlab’s medical device efficacy and safety studies capabilities.

Source: Citoxlab Group


lorem ipsum